Vera Therapeutics Inc Cl A (VERA) Stock Price, Quote & News

Company Profile

Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a fully humanized TACI-Fc fusion protein that binds B-cell activating factor (BAFF) and A proliferation-inducing ligand (APRIL), which is self-administered at home as a subcutaneous injection being evaluated for the treatment of immunoglobulin A nephropathy (IgAN) and other autoimmune...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 770 0077

Website: veratx.com

Address:

2000 Sierra Point Parkway, Suite 1200, Brisbane, United States

flamingojack Apr. 25 at 11:31 AM

$VERA didn’t the bears see what just happened with $TVTX ? Why sign up for that kind of pain?

0 · Reply

bonniewinter Apr. 24 at 5:52 PM

$VERA In a free fall over past week; dropping like a falling knife from $44 to $36 after CEO dumped $1M worth of shares

3 · Reply

philosophernutz Apr. 23 at 9:46 PM

$VERA VERA is attacking the disease from two angles. While competitors like Otsuka focus on one target, Vera's drug, atacicept, is a dual inhibitor that targets: APRIL (A PRoliferation-Inducing Ligand) BAFF (B-cell Activating Factor) Why the "Dual Hit" Matters In IgA Nephropathy, your body produces "glitchy" antibodies that clog up the kidneys. Here is how Vera's two-pronged attack works compared to the competition: Targeting APRIL: This shuts down the mature plasma cells that are currently pumping out the harmful IgA antibodies. It’s like stopping the workers on a factory assembly line. Targeting BAFF: This is Vera's "secret sauce." BAFF is a survival factor for B-cells at earlier stages of development. By hitting BAFF, Vera prevents the next generation of "bad" cells from ever reaching the factory floor. The Strategic Edge By attacking both BAFF and APRIL, atacicept aims for a deeper and more durable reduction of the toxic IgA levels.

0 · Reply

Quantumup Apr. 21 at 12:05 PM

Oppenheimer⬆️the PT on $CLYM to $18 and reiterated Outperform $TVTX $VERA LLY BIIB VRDN AMGN RHHBY Oppenheimer said: We take the opportunity to raise our PT to $18 (from $10) ahead of upcoming clinical reveals, which will show us how subcutaneous budoprutug as well as CLYM116 (also given subQ) perform in healthy volunteers. Our model had not previously included any value for '116, in development for IgA nephropathy (IgAN), yet we view it as exciting as budo—perhaps more so. Please see our IgAN primer. We believe '116 offers best-in-class potential among anti-APRILs, and several de-risking precedents provide visibility on its path to potential commercialization. We expect share outperformance to continue (+124% YTD vs. XBI +13%) as the company approaches key updates on both of its clinical assets.

0 · Reply

philosophernutz Apr. 17 at 10:37 PM

$VERA The "Big Three" Catalyst UpdateFDA PDUFA Date: The deadline is July 7, 2026. The FDA has granted Priority Review, meaning they are fast-tracking the decision because atacicept could be a game-changer.Commercial Launch: Management confirmed in their latest briefing that they are "battle-ready" for a mid-2026 launch. They've already hired a Chief Legal Officer (Jane Wright-Mitchell) and added heavy hitters to the board to prep for the transition from R&D to a sales powerhouse.PIONEER Results: Expect initial data from the PIONEER Phase 2 basket trial any day now (1H 2026). This will tell us if atacicept can move beyond IgAN into other massive kidney markets like Membranous Nephropathy.

0 · Reply

biotechworld Apr. 16 at 7:29 PM

$VERA Institutional holding more than 100%??? Shorted by more than 18% and price target way higher.....

0 · Reply

flamingojack Apr. 15 at 11:20 PM

this was the only issue for me. The recent controversies are concerning, although they have nothing to do with $VERA I would prefer an ethically adjusted firm. Ask Arthur Andersen how scandals pan out. 100% bullish on $VERA

0 · Reply

Irish_lass Apr. 14 at 6:03 PM

$VERA Way to quiet in here. Tidbit for the day: trials showed that atacicept not only reduces proteinuria but also stabilizes kidney function (eGFR) and reduces hematuria, suggesting it may slow or stop disease progression rather than just addressing symptom relief.

1 · Reply

Quantumup Apr. 14 at 11:20 AM

H.C. Wainwright reiterated $TVTX Buy; $47 $VERA $NVS RHHBY - IONS Cantor reiterated TVTX Overweight Here's what H.C. Wainwright and Cantor said in their notes to investors: https://x.com/Quantumup1/status/2044012394154709225?s=20

0 · Reply

bxlams Apr. 13 at 1:06 PM

$VRDN & $VERA adding this two soon

0 · Reply

Vera Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mar 25, 2026, 7:30 AM EDT - 4 weeks ago

Vera Therapeutics Appoints Jane Wright-Mitchell as Chief Legal Officer

Mar 5, 2026, 9:00 AM EST - 7 weeks ago

Vera Therapeutics Appoints Christopher Hite to Board of Directors

Mar 3, 2026, 11:10 AM EST - 7 weeks ago

Vera Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Feb 26, 2026, 7:30 AM EST - 2 months ago

Vera Therapeutics Provides Business Update and Reports Full Year 2025 Financial Results

Feb 24, 2026, 8:00 AM EST - 2 months ago

Vera Therapeutics to Participate at Upcoming Investor Conferences

Jan 28, 2026, 7:30 AM EST - 3 months ago

Vera Therapeutics Announces Appointment of Matt Skelton to Chief Commercial Officer

Jan 13, 2026, 5:15 PM EST - 3 months ago

Vera Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 7, 2026, 12:29 PM EST - 3 months ago

FDA Fast-Tracks Vera's At-Home Kidney Drug

Jan 7, 2026, 7:30 AM EST - 3 months ago

Vera Therapeutics Announces U.S. FDA Granted Priority Review to Biologics License Application for Atacicept for Treatment of Adults with IgA Nephropathy

Jan 6, 2026, 2:31 PM EST - 3 months ago

Wells Fargo sees short squeeze ahead: here are three stocks to play it

HRI MTDR

Dec 9, 2025, 8:57 PM EST - 4 months ago

Vera Therapeutics Announces Pricing of Public Offering of Class A Common Stock

Dec 8, 2025, 4:01 PM EST - 4 months ago

Vera Therapeutics Announces Proposed Public Offering of Class A Common Stock

Dec 3, 2025, 4:00 PM EST - 5 months ago

Vera Therapeutics Transcript: Citi Annual Global Healthcare Conference 2025

Dec 2, 2025, 8:45 AM EST - 5 months ago

Vera Therapeutics Transcript: Evercore ISI 8th Annual HealthCONx Conference

Nov 26, 2025, 4:05 PM EST - 5 months ago

Vera Therapeutics Appoints Veteran Biotech Executive James R. Meyers to its Board of Directors

Nov 13, 2025, 1:30 PM EST - 5 months ago

Vera Therapeutics Transcript: TD Cowen Immunology and Inflammation Summit

Nov 10, 2025, 7:29 AM EST - 5 months ago

Vera Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit

Nov 7, 2025, 6:27 PM EST - 6 months ago

Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy

Nov 6, 2025, 4:30 PM EST - 6 months ago

Vera Therapeutics Transcript: KOL Event

Nov 6, 2025, 9:51 AM EST - 6 months ago

Vera Therapeutics Announces Positive ORIGIN Phase 3 Data for Atacicept in IgA Nephropathy Presented at ASN Kidney Week 2025 and Published in the New England Journal of Medicine

Nov 5, 2025, 7:29 AM EST - 6 months ago

Vera Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results

Oct 22, 2025, 8:00 AM EDT - 6 months ago

Vera Therapeutics to Host an Investor Call and Webcast to Provide an ORIGIN 3 Update on November 6, 2025 at 4:30 pm ET

Oct 17, 2025, 9:12 AM EDT - 6 months ago

Vera Therapeutics Announces ORIGIN 3 Late-Breaking Abstract Selected as Featured Oral Presentation at Opening Plenary Session of ASN Kidney Week 2025

Sep 4, 2025, 9:10 AM EDT - 8 months ago

Vera Therapeutics Transcript: Cantor Global Healthcare Conference 2025

Aug 5, 2025, 7:00 AM EDT - 9 months ago

Vera Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results

Jul 10, 2025, 7:05 PM EDT - 10 months ago

Vera Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 11, 2025, 3:15 PM EDT - 11 months ago

Vera Therapeutics Transcript: Goldman Sachs 46th Annual Global Healthcare Conference 2025

Jun 4, 2025, 4:05 PM EDT - 11 months ago

Vera Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

Jun 3, 2025, 6:30 AM EDT - 11 months ago

Vera Therapeutics Announces Refinancing of Existing Oxford Debt Facility, Providing up to $500 Million of Term Loans

Jun 2, 2025, 9:01 AM EDT - 11 months ago

Kidney Health-Focused Vera Therapeutics Stock Price Spikes On Heels Of Successful Trial Data

Jun 2, 2025, 8:45 AM EDT - 11 months ago

Vera shares skyrocket as kidney disease drug succeeds in late-stage trial

Jun 2, 2025, 8:00 AM EDT - 11 months ago

Vera Therapeutics Transcript: Study Result

Jun 2, 2025, 6:30 AM EDT - 11 months ago

Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy

May 6, 2025, 8:00 AM EDT - 1 year ago

Vera Therapeutics Provides Business Update and Reports First Quarter 2025 Financial Results

Apr 3, 2025, 8:00 AM EDT - 1 year ago

Vera Therapeutics Completes Full Enrollment in Pivotal ORIGIN Phase 3 Trial for Atacicept in IgAN

Mar 4, 2025, 9:10 AM EST - 1 year ago

Vera Therapeutics Transcript: TD Cowen 45th Annual Healthcare Conference

Feb 27, 2025, 8:00 AM EST - 1 year ago

Vera Therapeutics to Participate in the TD Cowen 45th Annual Health Care Conference

Feb 26, 2025, 8:25 AM EST - 1 year ago

Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Jan 22, 2025, 6:46 AM EST - 1 year ago

Top 3 Health Care Stocks That Could Blast Off This Quarter

RDNT VKTX

Jan 13, 2025, 7:30 PM EST - 1 year ago

Vera Therapeutics Transcript: 43rd Annual J.P. Morgan Healthcare Conference 2025

Jan 7, 2025, 4:05 PM EST - 1 year ago

Vera Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

Dec 5, 2024, 7:55 AM EST - 1 year ago

Vera Therapeutics Transcript: 7th Annual Evercore ISI HealthCONx Conference

Nov 13, 2024, 9:30 AM EST - 1 year ago

Vera Therapeutics Transcript: Guggenheim Securities Inaugural Healthcare Innovation Conference

Oct 28, 2024, 10:33 AM EDT - 1 year ago

Vera Therapeutics' Atacicept Shows Sustained, Substantial Improvement In Kidney Function For Patients At Almost Two Years

Oct 28, 2024, 8:00 AM EDT - 1 year ago

Vera Therapeutics Transcript: Study Result

Oct 26, 2024, 7:30 PM EDT - 1 year ago

Vera Therapeutics Announces 96-week eGFR Stabilization in ORIGIN Phase 2b Study of Atacicept in IgAN in a Late-Breaking Oral Presentation at the American Society of Nephrology Kidney Week 2024

Oct 2, 2024, 8:00 AM EDT - 1 year ago

Vera Therapeutics Transcript: R&D Day 2024

Oct 2, 2024, 6:30 AM EDT - 1 year ago

Vera Therapeutics Announces Expanded Atacicept Development Program In Multiple Autoimmune Kidney Diseases

Oct 2, 2024, 6:30 AM EDT - 1 year ago

Vera Therapeutics Announces Late-Breaking Oral Presentation of ORIGIN Phase 2b Long-term Results at the American Society of Nephrology Kidney Week 2024

Sep 18, 2024, 9:10 AM EDT - 1 year ago

Vera Therapeutics Transcript: 2024 Cantor Fitzgerald Global Healthcare Conference

Sep 3, 2024, 7:49 AM EDT - 1 year ago

Load Up on Adobe Stock and These 2 Others This September, J.P. Morgan Says

ADBE CZR KYTX

Aug 8, 2024, 8:00 AM EDT - 1 year ago

Vera Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results

Jun 11, 2024, 4:01 PM EDT - 2 years ago

Vera Therapeutics Appoints Christy J. Oliger to Board of Directors

Jun 7, 2024, 4:05 PM EDT - 2 years ago

Vera Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference

May 28, 2024, 8:00 AM EDT - 2 years ago

Vera Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for Atacicept in Immunoglobulin A Nephropathy (IgAN)

May 25, 2024, 9:40 AM EDT - 2 years ago

Vera Therapeutics Presents 72-week eGFR Stabilization and Rapid Hematuria Improvement in Phase 2b ORIGIN Study of Atacicept in IgAN at the 61st European Renal Association Congress

May 9, 2024, 8:00 AM EDT - 2 years ago

Vera Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results

Mar 20, 2024, 7:30 AM EDT - 2 years ago

Vera Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial Results

Mar 4, 2024, 2:10 PM EST - 2 years ago

Vera Therapeutics Transcript: 44th Annual TD Cowen Health Care Conference

Feb 28, 2024, 4:20 PM EST - 2 years ago

Vera Therapeutics to Participate at the 44th Annual TD Cowen Health Care Conference

Feb 2, 2024, 8:00 AM EST - 2 years ago

Vera Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference

Feb 1, 2024, 4:05 PM EST - 2 years ago

Vera Therapeutics Announces Closing of Upsized Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares in Public Offering of Class A Common Stock

Jan 29, 2024, 11:50 PM EST - 2 years ago

Vera Therapeutics Announces Pricing of Upsized Public Offering of Class A Common Stock

Jan 25, 2024, 8:00 AM EST - 2 years ago

Vera Therapeutics Transcript: R&D Day 2024

Jan 25, 2024, 6:30 AM EST - 2 years ago

Vera Therapeutics Presents Positive 72-Week Data Showing eGFR Stabilization in the Phase 2b ORIGIN Clinical Trial OLE in IgA Nephropathy

Jan 9, 2024, 6:00 PM EST - 2 years ago

Vera Therapeutics Transcript: J.P. Morgan 42nd Annual Healthcare Conference 2024

Jan 8, 2024, 8:01 AM EST - 2 years ago

Vera Therapeutics Announces Appointment of Industry Veterans Robert Brenner, M.D. as Chief Medical Officer and William D.

Dec 27, 2023, 8:00 AM EST - 2 years ago

Vera Therapeutics to Participate in the 42nd Annual J.P. Morgan Healthcare Conference

Jun 20, 2023, 8:00 AM EDT - 3 years ago

Vera Therapeutics Transcript: Study Result

Jan 30, 2023, 8:00 AM EST - 3 years ago

Vera Therapeutics Transcript: Study Update

Jan 10, 2023, 4:30 PM EST - 3 years ago

Vera Therapeutics Transcript: J.P. Morgan 41st Annual Healthcare Conference 2023

Jan 4, 2023, 8:00 AM EST - 3 years ago

Vera Therapeutics Transcript: Study Result

Nov 28, 2022, 2:00 PM EST - 3 years ago

Vera Therapeutics Transcript: Status Update

flamingojack Apr. 25 at 11:31 AM

$VERA didn’t the bears see what just happened with $TVTX ? Why sign up for that kind of pain?

0 · Reply

bonniewinter Apr. 24 at 5:52 PM

$VERA In a free fall over past week; dropping like a falling knife from $44 to $36 after CEO dumped $1M worth of shares

3 · Reply

philosophernutz Apr. 23 at 9:46 PM

0 · Reply

Quantumup Apr. 21 at 12:05 PM

0 · Reply

philosophernutz Apr. 17 at 10:37 PM

0 · Reply

biotechworld Apr. 16 at 7:29 PM

$VERA Institutional holding more than 100%??? Shorted by more than 18% and price target way higher.....

0 · Reply

flamingojack Apr. 15 at 11:20 PM

0 · Reply

Irish_lass Apr. 14 at 6:03 PM

1 · Reply

Quantumup Apr. 14 at 11:20 AM

0 · Reply

bxlams Apr. 13 at 1:06 PM

$VRDN & $VERA adding this two soon

0 · Reply

SK8RS Apr. 13 at 1:12 AM

$VERA think ill keep holding

1 · Reply

Theflash88 Apr. 10 at 11:05 PM

$VERA Ok.. a stock like this doesn’t jump up 10% for no reason! Something will happen soon.. imho

0 · Reply

topstockalerts Apr. 10 at 5:29 PM

$VERA wouldn’t be surprised to see another push if this keeps holding

1 · Reply

Merlintrader Apr. 10 at 5:28 PM

$VERA April 2026 Deep Dive https://www.merlintrader.com/vera-therapeutics-april2026-dd/

0 · Reply

Irish_lass Apr. 10 at 4:49 PM

$VERA Still very

0 · Reply

EingeLTrade Mar. 31 at 5:22 PM

$VERA

0 · Reply

Quantumup Mar. 30 at 10:41 AM

Jefferies🏁 $VOR Buy; $50 $REGMF $VERA OTSKY ARGX VRTX TVTX NVS AUPH Here's what Jefferies said in its note: https://x.com/Quantumup1/status/2038566189970903309?s=20

0 · Reply

BioTechHealthX Mar. 29 at 3:04 PM

$VERA Vera Therapeutics (NASDAQ: VERA) is showing strong relative performance in the biotech sector. With clinical progress and growing momentum, investors are taking notice. https://biotechhealthx.com/biotech-news/is-it-a-good-timing-to-go-long-on-vera-therapeutics-vera/

0 · Reply

flamingojack Mar. 19 at 7:21 PM

$VERA nice little run up today 😎

0 · Reply

septrading Mar. 11 at 9:19 PM

$VERA Deep Track Capital just filed a 13G.

0 · Reply

notreload_ai Mar. 10 at 3:08 PM

$VERA , $VRTX ... BofA reaffirms Buy on Vera Therapeutics; Vertex’s povetacicept Phase 3 interim results in IgAN meet expectations but pose no major competitive threat. https://notreload.xyz/vertex-povetacicept-igan-data-no-threat-to-vera-atacicept-bofa/

1 · Reply

OptionRunners Mar. 10 at 2:36 PM

They appear to be adding to the $VERA calls at $5.67 but spreads are really wide. Could be closing, we'll have to see the OI change tomorrow.

1 · Reply

Market Cap	2.74B
Revenue (ttm)	0.00
Net Income (ttm)	-299.61M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.12

Volume	1,721,900
Avg Vol	1,225,882
Day's Range	N/A - N/A
Shares Out	71.36M
Stochastic %K	15%
Beta	1.17
Analysts	Strong Sell
Price Target	$79.00